Research article
Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis
- † Equal contributors
1 Department of Anatomy and Cell Biology, University of Ulsan College of Medicine, Seoul 138-736, Korea
2 Department of Medicine, Graduate School, Cellular Dysfunction Research Center and BMIT, University of Ulsan College of Medicine, Seoul 138-736, Korea
3 Department of Natural Science, College of Natural Science, Sang-Ji University, Wonju 220-702, Korea
4 Department of Internal Medicine, Division of Rheumatology, University of Ulsan College of Medicine, Seoul 138-736, Korea
5 Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford CA 94305, USA
Arthritis Research & Therapy 2012, 14:R14 doi:10.1186/ar3693
Published: 20 January 2012Additional files
Additional file 1:
Characteristics of patients with rheumatoid arthritis (RA). All patients were 30 years or older at the time of RA diagnosis and their mean ± SD age was 53.3 ± 16.0 years. All patients were positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody and had a diagnosis of RA with a median baseline Disease Activity Score 28 (DAS28) of 5.27 (range 2.9 to 7.4), a median 1 year DAS28 of 2.58 (1.7 to 3.4), a baseline median erythrocyte sedimentation rate of 69.6 (28 to 120), and a median baseline C-reactive protein (CRP) of 1.05 (0.1 to 2.04). With regard to medications used for the treatment of RA, patients were treated with prednisolone and disease-modifying antirheumatic drugs (DMARDs) including methotrexate, sulfasalazine, leflunomide, FK506, and/or hydroxychloroquine. SD, standard deviation.
Format: DOC Size: 181KB Download file
This file can be viewed with: Microsoft Word Viewer
